Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/2/2018 |
| Start Date: | September 1, 2017 |
| End Date: | May 29, 2019 |
Investigating the Association of Type of Anticoagulation Treatment for Non-valvular Atrial Fibrillation and Risk of Bleeding in England
Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs
(Novel Oral Anticoagulants) in routine clinical practice in England
(Novel Oral Anticoagulants) in routine clinical practice in England
Inclusion Criteria:
- Diagnosis of atrial fibrillation at or prior to index (the initiation of treatment)
- Incident prescription of an oral anticoagulant (index date)
- Patients with at least one year of computerized data prior to index date
Exclusion Criteria:
- Patients identified with a diagnosis of mechanical heart valve replacement or mitral
stenosis identified at any point in the pre-index period in either CPRD by Read codes
or in HES as ICD-10/OPCS codes
- Patients with indication of venous thromboembolism (pulmonary embolism or deep vein
thrombosis) identified in in either CPRD by Read codes or HES by ICD-10/OPCS codes
within 3 months prior to index
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
